154 related articles for article (PubMed ID: 21357709)
1. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
[No Abstract] [Full Text] [Related]
2. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
3. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Krauth MT; Herndlhofer S; Schmook MT; Mitterbauer-Hohendanner G; Schlögl E; Valent P
Haematologica; 2011 Jan; 96(1):163-6. PubMed ID: 20934998
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
5. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
6. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Kim D; Goh HG; Kim SH; Cho BS; Kim DW
Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
[TBL] [Abstract][Full Text] [Related]
7. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Chen J; Zheng Z; Shen J; Zhou Y
Leuk Lymphoma; 2010 May; 51(5):941-3. PubMed ID: 20350280
[No Abstract] [Full Text] [Related]
8. Dasatinib-induced pleural effusions: a lymphatic network disorder?
Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
[TBL] [Abstract][Full Text] [Related]
9. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D; Gorospe G; Yang AS
J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
[TBL] [Abstract][Full Text] [Related]
10. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Visani G; Breccia M; Montefusco E; Morra E; Santini V; Isidori A
Haematologica; 2011 Apr; 96(4):e23-4; author reply e25. PubMed ID: 21454871
[No Abstract] [Full Text] [Related]
11. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
13. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
14. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Kelly K; Swords R; Mahalingam D; Padmanabhan S; Giles FJ
Target Oncol; 2009 Apr; 4(2):99-105. PubMed ID: 19381453
[TBL] [Abstract][Full Text] [Related]
15. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
[TBL] [Abstract][Full Text] [Related]
16. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
[TBL] [Abstract][Full Text] [Related]
17. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib in chronic myelogenous leukemia.
Kathula SK
N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
[No Abstract] [Full Text] [Related]
19. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]